Prevenar 13
Pneumococcal Infection
Poitiers University HospitalvaccinePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Pneumococcal Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Conjugated Pneumococcal Vaccine Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Phase 4 | BBB |
Ppsv23 Poitiers University Hospital | Phase 4 | BB |
Prevnar 20 Poitiers University Hospital | Phase 4 | BB |
Prevnar 13 Merck Sharp & Dohme LLC | Phase 3 | BB |
v114 Merck Sharp & Dohme LLC | Phase 3 | BB |
View all 9 →
Same molecule, other indications
Prevenar 13 is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative · Phase 3
54 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →